5-取代苯基-3-吡唑烷酮衍生物的合成及抗癫痫作用研究

目的　寻找具有抗癫痫作用的化合物。方法　以取代苯甲醛为起始原料经缩合、酯化、环合及酰化得目标化合物,对所得化合物采用最大电惊厥法测定其抗癫痫活性。结果　合成了7个未见文献报道的5 取代苯基3 吡唑烷酮衍生物。结论　初步药理实验表明,化合物4c、4e显示出较强的抗癫痫活性。     

4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其对血小板聚集的抑制作用

目的:合成新的哒嗪酮类化合物,并研究其抗血小板凝集活性.方法:在6-(4-氯乙酰氨基苯基)-4,5-二氢-3(2H)哒嗪酮引入不同取代哌嗪,合成一系列化合物,并经过1H-NMR等确证;参考Born方法进行体外药理实验.结果:所有化合物都具有抗血小板凝集的活性,其中化合物(1)、(4)的抗血小板凝集活性明显优于MCI-154.结论:4-位取代哌嗪环基的引入对化合物抗血小板凝集的活性有显著影响.     

4-(2-乙酰氧基苯甲酰氨基)丁酸酯类化合物的设计、合成及抗癫痫活性研究

以中枢抑制性神经递质γ-氨基丁酸(GABA)受体调节位点为靶点,以GABA(1)为原料设计合成了12个未见文献报道的4-(2-乙酰氧基苯甲酰氨基)丁酸及酯类化合物(7a～7k)。目标化合物经IR、1H MNR、EI-MS及元素分析确证了结构。初步体外活性表明,所合成的化合物具有不同程度的抗癫痫活性,其中化合物7i～7k具有很好的抗癫痫活性,值得进一步研究,化合物4、7d～7h显示较好的抗癫痫活性。在此基础上,初步讨论了该类化合物的构效关系。     

4-取代-5-苯基-3-吡唑烷酮类化合物的合成及抗惊构效关系的研究

本文研究了4-取代-5-苯基-3-吡唑烷酮类化合物的结构与抗惊活性关系。共合成了6个3-吡唑烷酮类衍生物。其中,3-吡唑烷酮类化合物的4位引入取代基后,均使抗惊活性降低。这可能是因为3-吡唑烷酮类化合物结构中,羰基是生物活性中心,羰基的4位引入取代基会阻碍与受体的结合,使活性降低。     

4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮的合成及抗惊厥作用研究

目的筛选抗惊厥活性的化合物,寻找新型抗癫痫药物。方法以肉桂酸为原料,对其化学结构进行优化,合成了4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮。采用最大电休克发作实验(MES)测定其抗癫痫活性。结果采用红外光谱、核磁共振氢谱和质谱确定了化学结构。经药理活性筛选发现4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮具有抗惊厥作用。结论本合成路线简单、产物易分离,为开发新的抗癫痫药物提供了新思路。     

N-取代苯基-2-(4-取代苯基)环丙烷-1-甲酸乙酯-1-酰胺的设计、合成及抗肿瘤活性

目的设计、合成N-取代苯基-2-(4-取代苯基)环丙烷-1-甲酸乙酯-1-酰胺类化合物,并进行抗肿瘤活性研究。方法采用微波反应,经缩合、环化、水解以及酰胺化等反应合成目标化合物。所合成化合物经1H NMR谱图和质谱进行确证,并对其进行体外抗肿瘤活性筛选。结果设计、合成了20个环丙烷酰胺类化合物。体外药理活性实验显示,所合成的目标化合物具有较好的抗肿瘤活性,其中5b对A549细胞的IC50值为6.8μM,具有进一步研究的价值。结论对氯苯基取代化合物比对三氟甲基苯基取代化合物有更好的抗肿瘤活性;酰胺芳香环吸电子基团化合物活性优于供电子基团化合物。     

4-苯磺酰氧基-苯并口恶唑酮衍生物的合成及其抗炎镇痛作用

目的合成天然产物4-取代苯并口恶唑酮衍生物并对其抗炎镇痛活性进行初步评价。方法以2-氨基间苯二酚为原料,与三光气缩合制得4-羟基-苯并口恶唑酮;以2-取代苯酚为起始物,经取代、重排、氧化反应得到取代苯磺酰氯,取代磺酰氯与4-羟基-苯并口恶唑酮反应制得4-苯磺酰氧基-苯并口恶唑酮酯类化合物。采用二甲苯致小鼠耳肿胀法和小鼠醋酸扭体法测定目标化合物的抗炎及镇痛活性。结果与结论共合成了11个目标化合物,其中10个化合物未见文献报道,目标化合物的结构经ESI-MS、1H-NMR、13C-NMR谱确证;活性实验结果显示,化合物5g具有一定的抗炎活性,化合物5a、5d、5j具有较好的镇痛活性。     

4-色满酮Mannich碱类化合物的合成及其抗炎活性

目的设计合成一些4-色满酮Mannich类化合物,并且考察其抗炎活性.方法以取代的4-色满酮为原料,经过Mannich反应合成4-色满酮Mannich碱类化合物,并测定了目标化合物的抗炎活性.结果合成了17种4-色满酮Mannich碱类化合物,并经元素分析、红外光谱、核磁共振氢谱确证这些化合物的结构,药理活性筛选结果表明:大多数化合物具有显著的抗炎活性.     

4,5-二氢-3(2H)-哒嗪酮衍生物的合成及抑制血小板聚集作用

目的设计并合成6-(4-取代苯基)-4,5-二氢-3(2H)-哒嗪酮衍生物,并对其抗血小板聚集活性进行初步评价.方法以苯酚为原料,经多步反应合成目标化合物,并以Born比浊法测试目标化合物的抗血小板聚集活性.结果共合成16个新化合物,经MS、1H-NMR确证其结构.其中12个化合物具有一定的抗血小板聚集活性.结论中间连接链的长度影响此类化合物抑制血小板聚集活性.当n=3、4时,所有化合物均具有一定的活性;当n=2时,仅有两个化合物具有活性.     

4-甲氧基-N,N′-二(2-取代苯基)-1,3-苯二磺酰胺类化合物的合成及体外抗血小板聚集活性研究

目的 寻找新的抗血小板聚集药物并研究4-甲氧基-N,N′-二(2-取代苯基)- 1,3-苯二磺酰胺类化合物的不同2-位取代苯基对抗血小板聚集活性的影响。方法 以吡考他胺为先导化合物,用取代苯磺酰氨基代替3-吡啶甲氨基对先导化合物进行结构改造：以苯甲醚为原料,采用文献方法与氯磺酸反应直接制得重要中间体4-甲氧基-1,3-苯二磺酰氯;该中间体与2-取代苯胺类化合物经胺解反应制得目标化合物。以吡考他胺和阿司匹林为阳性对照药物,采用Born比浊法对目标化合物进行体外抗血小板聚集活性初筛。结果与结论 共制得12个化合物(4a~4l),其化学结构由IR、1H-NMR和MS光谱确证,其中9个化合物(4a~4c, 4e~4i和4l)未见文献报道。药理试验结果表明,5个化合物表现出较好的体外抗血小板聚集活性：化合物4g、4f和4b的活性优于吡考他胺和阿司匹林;化合物4i的活性略低于阿司匹林;化合物4h的活性与吡考他胺相当。     

Anticonvulsant Activity of Novel 1-(Substituted Benzylidene)-4-(1-(Morpholino/Piperidino Methyl)-2,3-Dioxoindolin-5-yl) Semicarbazide Derivatives in Mice and Rats Acute Seizure Models

A series of novel 1-(substituted benzylidene)-4-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl) semicarbazides 6a-6t was designed and synthesized on the basis of semicarbazide-based pharmacophoric model to meet the structural requirements necessary for anticonvulsant activity. The compounds were subjected to in vivo antiepileptic evaluation using maximal electroshock test and subcutaneous pentylenetetrazole seizure test methods. The neurotoxicity was determined by rotorod test. In the preliminary screening, compounds 6c, 6d, 6g, 6h, and 6m were found active in maximal electroshock test model, while 6g, 6i, 6m, and 6o showed significant antiepileptic activity in subcutaneous pentylenetetrazole seizure test model. Further, the compounds 6c, 6d, 6g, 6h, 6i, and 6m were administered orally to rats, of which 6c and 6g showed better activity than phenytoin. Among the synthesized compounds, 6g revealed excellent protection in both models with lower neurotoxicity.     

4-(2-乙酰氧基苯甲酰氨基) 丁酰胺衍生物的设计、合成及初步活性研究

为了寻找新型γ-氨基丁酸 (γ-aminobutyric acid, GABA) 类抗癫痫药物, 以抑制性神经递质γ-氨基丁酸受体 (GABA_R) 为作用靶点, 以GABA为原料设计合成了一类全新结构类型的4-(2-乙酰氧基苯甲酰氨基) 丁酰胺类化合物 (5a～5l), 通过IR、¹H MNR、EI-MS及元素分析确证了目标化合物的结构。初步药理活性评价结果表明, 目标化合物具有良好抗癫痫活性, 值得进一步研究, 在此基础上, 初步讨论了该类化合物的构效关系。     

Designing of antiepileptic ligands by esterification and acetylation of dipeptides

Glycylglycine, alanylalanine and alanylglycine were synthesized, their free carboxylic and amino groups were converted to methyl esters of N-acetylglycylglycine, N-acetylalanylglycine and N-acetylalanylalanine. The synthesized compounds were evaluated for antiepileptic activity, plasmaprotein binding, TD₅₀ and potentiating effect of phenobarbitone sodium.     

Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy

A series of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines derivatives was synthesized and evaluated for anticonvulsant activity. The compounds were screened in mice for their ability to antagonize maximal electroshock- and bicuculline-induced seizures; neurotoxicity was evaluated in the rotorod test. The anticonvulsant activity of the most potent compounds in this series was also examined in kindled amygdaloid rats and in photoepileptic Papio papio baboons. Phenobarbital, diphenylhydantoin, carbamazepine, and sodium valproate were used as standard antiepileptic drugs. The structure-activity relationships in this series were examined by either varying the aryl ring in the 6-position of the pyridazine ring or by modifying the 3-amino side chain. Only the compounds with a phenyl ring in the 6-position of the pyridazine ring exhibited appreciable anticonvulsant activity. Furthermore, a 4-hydroxypiperidine side chain in the 3-position of the pyridazine ring appeared essential for anticonvulsant activity. Substituting the phenyl ring with a Cl in the 2-position led to a substantial increase of activity; disubstituting the phenyl ring with a Cl in the 2- and 4-positions yielded the most potent compounds in this series, some of which were as potent or more potent than phenobarbital. Two compounds, 6-(2-chlorophenyl)-3-(4-hydroxypiperidino)pyridazine (2) and 6-(2,4-dichlorophenyl)-3-(4-hydroxypiperidino)pyridazine (3), were selected for further studies. Clinical evaluation of these compounds is in progress.     

Structure and anti-proliferation function of 5,5-diphenyl-2-thiohydantoin (DPTH) derivatives in vascular endothelial cells

Previously, we identified DPTH, an analogue of antiepileptic drug phenytoin (5,5-diphenylhydantoin, DPT), capable of retarding the cell cycle in the human vascular endothelial cells. Our data suggest that DPTH inhibits human umbilical venous endothelial cells (HUVEC) proliferation by increasing the level of p21 protein, which in turn inhibits the activities of cyclin-dependent kinase (CDK)2 and CDK4, and finally interrupts the cell cycle. To search chemicals with more potency in anti-angiogenic activity, we designed and synthesized several chemical compounds based on the structure-activity relationship consideration. We evaluated the anti-angiogenic activity of these compounds by examining their effects on DNA synthesis, cell number, p21 induction and capillary-like tube formation. Our results showed that introduction of side chain containing an aromatic ring structure with right spatial arrangement at sulfur atom of DPTH enhanced the anti-angiogenic activity in HUVEC.     

Synthesis, characterization & anticonvulsant activity of amide derivatives of 4-amino-1,2-naphthoquinone

In the present study, 4-amino-1,2-naphthoquinone analogues were synthesized and characterized by spectroscopic (FT-IR, ¹H NMR and ¹³C NMR) and elemental analysis. The synthesized compounds were evaluated for anticonvulsant activity by the maximal electroshock (MES) test and subcutaneous pentylenetetrazole (sc. PTZ) test, the most widely employed seizure models for early identification of anticonvulsant candidates, whereas their neurotoxicity was examined by rotarod test. Compounds were administered to animals at different concentrations (10, 20 & 40 mg/kg) by intraperitonial (i.p.) route and the % seizure protection was measured. The pharmacological results revealed that majority of compounds were effective in MES and sc. PTZ tests. Compounds N-(1,2-dihydro-1,2-dioxonaphthalen-4-yl)butyramide (4) and N-(1,2-dihydro-1,2-dioxonaphthalen-4-yl)-3-methylbutanamide (6) were active at the dose 40 & 20 mg/kg, respectively, while compounds N-(1,2-dihydro-1,2-dioxonaphthalen-4-yl)hexanamide (7) and 4-acetamido-N-(1,2-dihydro-1,2-dioxonaphthalen-4-yl)benzamide (10) were active at the dose 10 mg/kg and emerged as the most active compounds of the series. These compounds showed anticonvulsant effect comparable to phenytoin which was used as reference antiepileptic drug. The above-mentioned compounds have diminutive neurotoxic effects so they can move on next phase of anticonvulsant drug development.     

Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-methyl-3-substituted quinazolin-4-(3H)-ones

A series of novel 2-methyl-3-substituted quinazolin-4-(3H)-ones have been synthesized by treating (2-methyl-4-oxo-3H-quinazolin-3-yl)dithiocarbamic acid methyl ester with different amines, the starting material dithiocarbamate was synthesized from anthranilic acid. The compounds synthesized were investigated for analgesic, anti-inflammatory and antibacterial activities. All the test compounds exhibited significant activity, the compounds VA2, VA3 and VA4 shown more potent analgesic activity, and the compounds VA3 and VA4 shown more potent anti-inflammatory activity than the reference compound diclofinac sodium.     

Synthesis and antiseizure evaluation of isoindoline-1,3-dione derivatives in mice

Epilepsy is the most common serious chronic noninfective neurological condition in the world. Despite the presence of various antiepileptic drugs in the market for epileptic patients, the necessity for development and discovery of novel antiepileptic drugs is felt. In fact, only 60–70 % of patients respond to the current drugs, and a high incidence of adverse effects is also observed. In the present study, a new series of phthalimide derivatives (compounds 3a–3m) were synthesized through the reaction of phthalic anhydride and various derivatives of aniline in toluene solvent (Reflux, 24 h). Antiepileptic activity of synthesized compounds (3a–3m) was investigated using two experimental models namely, maximal electroshock (MES) and pentylenetetrazole (PTZ), and the obtained results were compared with diazepam as reference drug. Neurotoxicity of compounds was also evaluated using rotarod model. Compound 3m with para methoxy substituent exhibited the anticonvulsant activity at 15.1 ± 1.53 (12.23–17.96) mg/kg dose in MES model compared to other derivatives. Unfortunately, none of the tested compounds rendered acceptable protection in subcutaneous PTZ model.